Scientific Programme

8th July 2010, Thursday
9.00-9.15	President's Welcome Speech
9.15-11.30	Scientific Session 1 - Immunology - Incorporating therapy Co-chairs Dr. Ina Kotter (Germany) and Dr Y. Kaneko (Japan)
	9.15 - 9.45	Outside speaker - Professor Adrian Hayday (UK) The evidence for lymphoid stress-surveillance of tissues
	9.45-10.15	ISBD invited speaker - Dr Bahram Bodaghi (France) Regulatory T-cells in non infectious uveitis : a new therapeutic strategy
	10.15-11.30	Selected speakers from abstracts O-001 Altered Expression of Costimulatory Molecules in Behçet's Disease According to Clinical Activity (Ref: 074) 1Ji Hyun Sim, M.d., 1Mi Jin Park, B.s., 2Sun Park, M.d., Ph.d., 1Eun-so Lee, M.d., Ph.d. 1Department of Dermatology, Ajou University School of Medicine, 2Department of Microbiology, Ajou University School of Medicine . O-002 Expression of pro-inflammatory protein S100A12 (EN-RAGE) in Behçet's disease and its association with disease activity (Ref:111) 1Eun Chun Han, 1Sung Bin Cho, 1Keun-jae Ahb, 1Sang Ho Oh, 1Jihyun Kim, 2Dong Soo Kim, 1Kwang Hoon Lee, 1Dongsik Bang . 1Department of Dermatology and Cutaneous Biology Research Institute, Yonsei University College of Medicine, Seoul, Korea, 22department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea O-003 Identification of JAK1 as a candidate inflammatory signalling pathway by genome-wide expression profiling in monocytes from patients with Behcet's Disease (Ref:159) 1H. Direskeneli, 4Jj. Boyle, 2Ft. Ozdemir, 3V. Yılmaz, 2E. Ekşioğlu-demiralp, 4D. Haskard, 3G. Saruhan-direskeneli . 1Department of Rheumatology, Marmara University, Faculty of Medicine, Istanbul, Turkey, 2Department of Immunology, Marmara University, Faculty of Medicine, Istanbul, Turkey, 3Department of Physiology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, 4Cardiovascular Sciences Centre, Imperial College, London, Uk O-004 A novel murine model of Behcet's-like eye disease associated with proteoglycan induced arthritis in the absence of gamma interferon. (Ref:263) 1Jelena Kezic, 1Michael Davey, 1Tibor Glant, 1Katie Dahlhausen, 1Stephen Planck, 1Tammy Martin, 1James Rosenbaum, 1Holly Rosenzweig . 1Casey Eye Institute, Oregon Health & Science University, Portland, Or., 2Veterans Affairs Medical Center, Portland, Or., 3Rush University Medical Center, Chicago, Il. O-005 The functional analysis of MICA polymorphism with an emphasis on Behcet's disease (Ref:314) 1Seema Shafi, 1Miles R Stanford, 1Graham R Wallace, 1Adrian C Hayday . 1Dept Immunobiology Guy's Hospital, 2Dept Ophthalmology St Thomas' Hospital, 3Academic Dept Ophthalmology, Birmingham
11.30-13.00	Coffee and posters
13.00-14.00	Lunch
14.00-16.15	Scientific session 2 - Vasculitis Co-chairs - Dr Michael Schirmer (Austria) and Professor Samir Assad-Khalili (Egypt)
	14.00-14.30	Outside speaker - Dr Justin Mason (UK) Imaging studies in large vessel vasculitis
	14.30-15.00	ISBD invited speaker - Professor Hasan Yazici The vasculitis of Behçet's syndrome: What do we know and not know?
	15.00-16.15	Selected speakers from abstracts O-006 Management of Thrombosis In 62 Patients With Behçet Syndrome Over 15 Years (Ref: 009) 1Puja Mehta, 2Mike Laffan, 1Dorian Haskard . 1Department of Rheumatology, Imperial College Healthcare NHS Trust, 2Department Of Haematology, Imperial College Healthcare NHS Trust O-007 Pulmonary Artery Hypertension in Behçet's Syndrome (Ref: 194) 1Emire Seyahi, 2Murat Baskurt, 1Melike Melikoglu, 3Canan Akman, 3Deniz Cebi Olgun, 4Eda Simsek, 1Vedat Hamuryudan, 1Serdar Kucukoglu, 1Hasan Yazici . 1Cerrahpasa Medical Faculty, Rheumatology Department, 2University of Istanbul, Institute of Cardiology, Department of Cardiology, 3Cerrahpasa Medical Faculty, Radiology Department, 4Cerrahpasa Medical Faculty, Internal Medicine Department O-008 Cutaneous Vasculitis in Behçet's Disease (Ref: 219) 1Ko-ron Chen . 1Saiseikai Central Hospital O-009 Pulmonary Perfusion Scintigraphy Findings in Behçet's Disease (Ref: 309) 1Fulya Cosan, 2Isik Adalet, 1Bahar Artim-esen, 1Orhan Aral, 1Ahmet Gul . 1Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul University, 2Istanbul Faculty of Medicine, Department Nuclear Medicine, Istanbul University O-010 Efficacy of Adalimumab in patients with Behçet's Disease unsuccessfully treated with Infliximab (Ref: 316) 1Salvatore d'Angelo, 1Ignazio Olivieri, 1Pietro Leccese, 1Angela Padula, 1Carlo Palazzi, 2Loredana Latanza. 1Rheumatology Department of Lucania, San Carlo Hospital of Potenza and Madonna Delle Grazie Hospital of Matera, Potenza and Matera; Italy, 2Section of Ocular Immunopathology, Department of Ophthalmology, "a.cardarelli" Hospital, Naples, Italy
16.15-16.30	Coffee Break
16.30-17.00	Debate - Autoimmunity vs autoinflammation Professor Haner Direkeneli and Dr Graham Wallace
17.15-18.00	Special lecture - Tom Greeves MA PhD (Archaeologist and Historian) & Chris Chapman (Photographer and Film Maker) to speak on 'Joined by the Ears - the Remarkable Journey of the Three Hares along the Silk Route from Ancient China to Devon...and the Bones!'.
18.00-20.00	Opening Cocktail in the Octagon, Queen Mary University of London
9th July 2010, Friday
9.15 -11.30	Scientific session 3 - Regional inflammation Co-chairs Dr Dongsik Bang (Korea) and Dr Wafa Madanat (Jordan)
	9.15- 9.45	Outside speaker Dr Dennis McGonigle (UK) Behcets Disease classification as an intermediate between adaptive and innate mediated immune disease
	9.45-10.15	ISBD invited speaker Dr Ahmet Gul (Turkey) Multiple faces of inflammation in Behcet's disease
	10.15-11.30	Selected speakers from abstracts O-011 Effects of infliximab in the treatment of refractory posterior uveitis of Behçet´s disease after withdrawal of infusions (Ref: 016) 1Alfredo Adan, 1Victoria Hernandez, 1Laura Pelegrin, 1Gerard Espinosa, 1Marina Mesquida, 1Raimon Sanmarti . 1Hospital Clinic Barcelona O-012 AIN457, a fully human monoclonal anti-interleukin-17A monoclonal antibody, for the adjunctive treatment of posterior segment uveitis secondary to Behçet's Disease: The SHIELD study (Ref: 062) 1Ilknur Tugal-tutkun, 1On Behalf of The Shield Study Group . 1Department of Ophthalmology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey O-013 Methotrexate in Ocular lesions of Behcet's Disease; a Longitudinal Study (Ref: 097) 1Fereydoun Davatchi, 1Bahar Sadeghi Abdollahi, 1Hormoz Shams, 1Farhad Shahram, 1Abdolhadi Nadji, 1Cheyda Chams-davatchi, 1Tahereh Faezi, 1Massoomeh Akhlaghi, 1Farima Ashofteh . 1Rheumatology Research Center, Tehran University of Medical Sciences O-014 Neuro-Behcet's disease in Japan: a multicenter retrospective survey (Ref: 104) 1Shunsei Hirohata, 2Hirotoshi Kikuchi, 3Tetsuji Sawada, 4Hiroko Nagafuchi, 5Masataka Kuwana, 6Mitsuhiro Takeno, 6Yoshiaki Ishigatsubo . 1Kitasato University School of Medicine, 2Teikyo University School of Medicine, 3Tokyo Medical University, 4St. Marianna University School of Medicine, 5Keio University School of Medicine, 6Yokohama City University Graduate School of Medicine O-015 A Comparative Study of Clinical, Endoscopic and Histologic Findings in Patients with Gastrointestinal Behçet's Disease and Crohn's Disease (Ref: 298) 1Aykut Ferhat Celik, 1Ibrahim Hatemi, 2Gulen Hatemi, 1Emine Satir, 1Yusuf Erzin, 1Gürhan Şişman, 3Suha Goksel, 4Orhan Sami Gültekin, 2Hasan Yazici . 1Istanbul University, Cerrahpasa Medical School, Gastroenterology, 2Istanbul University, Cerrahpasa Medical School, Rheumatology, 3Istanbul University, Cerrahpasa Medical School, Pathology, 4Endotip Diagnosis Center
11.30-13.00	Coffee and posters
13.00-14.00	Lunch
14.00-16.15	Scientific session 4 - Age-related BD Co-chairs - Dr Paul Brogan (UK) and Dr Martin van Hagen (Netherlands)
	14.00-14.30	Outside speaker - Professor Michael Beresford (UK) UK Paediatric Rheumatology Clinical Studies Group: Driving Forward Care & Understanding
	14.30-15.00	ISBD invited speaker Dr Isabelle Kone-Paut (France) Pediatric Behcet's Disease: diagnostic problems and treatment peculiarities
	15.00-16.15	Selected speakers from abstracts O-016 Ethnic and gender patterns of age distribution and duration of Adamantiades-Behçet's disease (ABD) course in Germany (Ref: 098) 1Nestor G. Papoutsis, 1Nikolaos G. Bonitsis, 1Andreas Altenburg, 1Helmut Orawa, 1Ina Kötter, 1Lothar Krause, 1Uwe Pleyer, 1Djalil Djawari, 1Rudolf Stadler, 1Uwe Wollina, 1Peter Kohl, 1Wilhelm Kirch, 1Falk Ochsendorf, 1Peter Martus, 1Christos C. Zouboulis . 1German Registryof Adamantiades- Behçet's Disease, Dessau, Germany, 2Institute of Medical Informatics, Biometry and Epidemiology, Charité Universitaetsmedizin Berlin, Berlin, Germany O-017 Systemic Involvements and Currently Preferred Immunosuppressive Agents In A Large Population Composed of Relatively Young Behcet's Patients From Countrywide (Ref: 166) 1Omer Karadag, 1Veli Yazisiz, 1Sedat Yilmaz, 1Battal Altun, 1Mustafa Gezer, 1Murat Karaman, 1Muhammet Cinar, 1Hakan Erdem, 1Salih Pay, 1Ayhan Dinc . 1Gulhane Schoolof Medicine, Rheumatology Division Ankara, Turkey O-018 Cross-sectional survey of neurologic and psychiatric symptoms in North American patients with Behcet's syndrome. (Ref: 250) 1Ilya Kister, Md, 2Maria Filopoulos, 2Monalyn De Los Reyes Labitigan, Md, 3Sara Crystal, Md, 4Matthew Robbins, Md, 1Joseph Herbert, Md, 2Yusuf Yazici, Md . 11. ms Care Center, Department of Neurology, NYU School of Medicine, Ny, 22. Behcet's Syndrome Evaluation, Treatment, Research Center, Department of Medicine, NYU School of Medicine, NY, 33. Department of Neurology, NYU School of Medicine, Ny, 44. Department of Neurology, Albert Einstein College of Medicine, Bronx, NY O-019 Eye disease in juvenile patients with Behçet's syndrome (Ref: 264) 1Yilmaz Ozyazgan, 2Emire Seyahi, 1Ahmet Sarica, 2Serdal Ugurlu, 2Gulen Hatemi, 2Sebahattin Yurdakul, 2Hasan Yazici . 1University of Istanbul, Cerrahpasa Medical Faculty, Department of Ophthalmology, 2University of Istanbul, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology . O-020 Work Disability In Behcet's Syndrome (Ref: 267) 1Gulen Hatemi, 1Vedat Hamuryudan, 1Koray Tascilar, 1Serdal Ugurlu, 1Hasan Yazici . 1Istanbul University, Cerrahpasa Medical School, Rheumatology
16.15-16.30	Coffee Break
16.30-17.00	Debate - Geographical differences in BD Professor Shigeaki Ohno (Japan) and Professor Miles Stanford (UK)
20.00	Gala Dinner in The Great Hall, St. Bartholomew's Hospital
10th July 2010, Saturday
9.00 -11.15	Scientific session 5 - Genetics Co-chairs - Dr Sofia Oliveira (Portugal) and Dr Jan van Laar (Netherlands)
	9.00-9.30	Outside speaker - Dr Oliver Brand (UK) Genetic of complex diseases:lessons from Graves' disease
	9.30-10.00	ISBD invited speaker Dr Eun-Bong Lee (Korea) Perspective of candidate gene analysis in Behcet's disease
	10.00-11.15	Selected speakers from abstracts O-021 Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphism in patients with Behcet disease (Ref: 060) 1Farhad Shahram, 2Niloofar Mojarad Shafiee, 3Mehrdad Behmanesh, 1Arash Tehrani Banihashemi, 1Alireza Faridar, 1Fereydoun Davatchi . 1Rheumatology Research Center, Tehran University of Medical Sciences, Tehran, Iran, 2Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran, 3Department of Genetic, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran O-022 Impact of HLA-B51(5) on Behçet's Disease Clinical Phenotype: Systematic Review and Meta-Analyses on Phenotype-Genotype Correlates (Ref: 129) 1Mahr Alfred, 1Maldini Carla, 1Cheminant Morgane, 2Lavalley Michael P., 1Guillevin Loïc . 1Hospital Cochin, Université de Paris 5, Paris, France, 2Boston University School of Public Health, Boston, Massachusetts, United States . O-023 Genome-wide association studies define two susceptibility loci for Behçet's disease (Ref: 185) 1Nobuhisa Mizuki, 1Akira Meguro, 2Masao Ota, 3Yeong Wook Song, 3Eun Bong Lee, 4Nobuyoshi Kitaichi, 5Kenichi Namba, 5Yukihiro Horie, 6Mitsuhiro Takeno, 7Sunao Sugita, 7Manabu Mochizuki, 8Seiamak Bahram, 6Yoshiaki Ishigatsubo, 9Hidetoshi Inoko, 10Shigeaki Ohno . 1Department of Ophthalmology and Visual Science, Yokohama City University Graduate School of Medicine, 2Department of Legal Medicine, Shinshu University School of Medicine, 3Department of Internal Medicine, Seoul National University College of Medicine, 4Department of Ophthalmology, Health Sciences University of Hokkaido, 5Department of Ophthalmology and Visual Sciences, Hokkaido University Graduate School of Medicine, 6Department of Internal Medicine and Clinical Immunology, Yokohama City University Graduate School of Medicine, 7Department of Ophthalmology and Visual Science, Tokyo Medical and Dental University Graduate School of Medicine, 8Laboratoire D'ımmunogénétique Moléculaire Humaine, Centre de Recherche d'Immunologie et d'Hématologie, Faculté de Médecine, Université de Strasbourg, 9Department of Molecular Life Science, Division of Molecular Medical Science and Molecular Medicine, Tokai University School of Medicine, 10Department of Ocular Inflammation and Immunology, Hokkaido University Graduate School of Medicine . O-024 A Twin Study In Behçet's Syndrome (Ref: 191) 1Seval Masatlioglu, 2Emire Seyahi, 3Eda Tahir Turanli, 2Izzet Fresko, 4Feride Gogus, 5Ebubekir Senates, 6Fatma Oguz Savran, 2Hasan Yazici . 1Division of Rheumatology, Haydarpaşa Numune Research and Education Hospital, 2Division of Rheumatology, Department of Medicine, Cerrahpaşa Medical Faculty, 3Molecular Biology and Genetics Department, Dr. Orhan Öcalgiray Molecular Biology and Genetic Research Center (mobgam), Istanbul Technical University, 4Department of Physical Medicine and Rehabilitation, Division of Rheumatology, University of Gazi, 5Division of Gastroenterology, Haydarpaşa Numune Research and, Education Hospital, 6Department of Medical Biology, Istanbul Medical Faculty, University of Istanbul O-025 A Genome-wide Association Study Identifies Common Variants of the IL10 and IL23R Genes that Contribute to Behçet's Disease Susceptibility (Ref: 224) 1Elaine F. Remmers, 2Fulya Cosan, 1Yohei Kirino, 1Michael J. Ombrello, 3Barbara Yang, 4Virginia G. Kaklamani, 5William E. R. Ollier, 6Dongsik Bang, 7Graham R. Wallace, 3Massimo Gadina, 1Daniel L. Kastner, 2Ahmet Gül . 1Laboratory of Clinical Investigation, National Institute of Arthritis and Musculoskeletal and Skin Diseases, 2Department of Internal Medicine, Istanbul Faculty of Medicine, 3Office of Science and Technology, National Institute of Arthritis and Musculoskeletal and Skin Diseases, 4Division of Hematology/oncology, Northwestern University, 5School of Immunity and Infection, University of Manchester, 6Dept of Dermatology, Yonsei University College of Medicine, 7Academic Unit of Ophthamology, Universtiy of Birmingham .
11.15-11.45	Coffee Break
11.45-12.00	Presentation of Awards
12.00-12.30	Closing Remarks Professor Songnack Lee (President)

General Notes

Scientific sessions
The aim of the conference organisers is to have the sessions based on concepts rather than BD in specific tissues. It is hoped that this will lead to the identification of common ground in the pathogenesis of the disease in different sites, and to highlight differences that may be important. The invitation of outside speakers should provide current knowledge in the particular fields that will inform and encourage participants
Scientific session 1
The aim of this session is to address the wider issues of the immune response in BD. Several publications report a Th1 polarised response yet in several tissues i.e. anterior chamber, joint and CNS it is reported as a predominantly a neutrophilic infiltrate. Moreover, roles for NKT, NK and T cells have all been implicated in the pathogenesis of BD. The session will seek, along with the related debate, to identify a common process and the kinetics of such a response.
Scientific session 2
Vasculitis is a common feature of many of the clinical manifestations of BD. However, it is still not clear which cells and processes are involved. For example, what are the differences between parenchymal and non-parenchymal CNS disease. What are the vascular responses in the skin in conditions such as erythema nodosum. Is the retinal vascular occlusion seen in BD due to neutrophil activation? Most importantly, is the endothelium of these sites activated and why. It is envisaged that these and other concepts will be addressed.
Scientific session 3
The current concept of regional inflammation is particularly relevant to BD. Why do certain patients get one manifestation and another a different form. Chris Buckley will discuss the role of fibroblasts in organising a particular microenvironment. Importantly, the potential difference between the inflammatory response at the mucosal surfaces compared to other immune privileged sites will be addressed. The effect of treatment on inflammation at different sites should also be discussed.
Scientific session 4
BD can occur at any age with a similar clinical picture in children and adults. In children diagnosis is a difficult problem as well as being a complicated treatment issue. It is not clear whether paediatric BD is the same condition as adult BD or what the outcome for juvenile patients will be. Similarly, should the same treatment be given to children as to adults? In addition BD has been reported to diminish with age. Is this due to the disease being less active or just to excessive tissue damage. Dr Kone-Paut will discuss the results of the paediatric BD database, and processes involved in childhood BD will be addressed.
Scientific session 5
BD has long been considered as having a genetic component. In this session current studies will be discussed. It is envisaged that genome-wide analysis studies currently underway will be presented. Similarly case controls studies of candidate genes in different ethnic groups will be discussed.

Debates
The plan is to hold two debates on current topics of general interest in BD. These debates will feature two selected individuals one who will speak for the proposal and one to speak against. Speakers will have 10 minutes to present their case, followed by 5 minutes each for a rebuttal. The questioning will then be opened up to the floor, before a vote (for fun) will be taken.

Debate 1 Autoimmunity versus auto inflammation
A case for BD being an auto inflammatory response has been presented in several recent publications. Is it therefore time to change the textbook definition of BD, or is autoimmunity still a better term to describe the responses seen in BD?

Debate 2 Geographical differences in BD
It has long been suggested that BD has a different clinical picture in different parts of the world. Can this be supported in the light of current data. If so what may be the causes of such differences. Data from Japan suggests that BD is decreasing, but is this seen in other countries?

Print this Page